Marsh, a global leader in insurance broking and risk management, today
announced that its Marsh Analytics Platform (MAP), a comprehensive
solution enabling clients to quantify and manage risk financing through
a notable combination of data, analytics, and technology, is now backed
by an industry leading proprietary global loss database, a trained
global team of sales professionals, and hundreds of devices with the
industry’s only mobile content-delivery platform, known as iMAP.
DAYTONA BEACH, FL--(Marketwired - November 03, 2014) - Brown & Brown, Inc. (the "Company") (NYSE: BRO) corrected certain errors contained in a press release issued by Zacks Investment Research, Inc. and resulting media reports that incorrectly reported that the Company failed to meet Zacks Investment Research's consensus estimate of earnings per share following the Company's October 17, 2014 press release announcing its results of operations for the third quarter ended September 30, 2014.
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) announced today that it has
received U.S.$515 million of commitments from banks that have agreed to
join the credit agreement entered into on September 30, 2014 (the
Following the completion of customary closing conditions, the banks that
provided the new commitments will accede the Credit Agreement as
additional lenders, increasing the total amount of the Credit Agreement
from U.S.$1.35 billion to U.S.$1.87 billion.
Umpqua Holdings Corporation (NASDAQ:UMPQ) (the “Company”) announced
today the commencement of a secondary public offering of 31,190,716
shares of the Company’s common stock, including 28,300,720 shares by
certain funds affiliated with Thomas H.
By Anthony Harrup
MEXICO CITY--The Mexican government on Monday awarded a $3.7 billion project to build a bullet train in central Mexico to a Chinese-led consortium, saying that the single bid met the project's technical and financial requirements.
Clinical programs advance on multiple fronts, with trial initiation, trial enrollment, data and IP milestones achieved and anticipated Commercial strategy reinforced with product acquisition and upcoming commercial launch Abstral ® (fentanyl) sublingual tablet net revenue was $1.6 million in Q3 2014 and $6.1 million to date this year, with reiterated guidance of $8-$10 million for the full year 2014 Zuplenz ® (ondansetron) Oral Soluble Film U.S. rights licensed; launch expected in Q1 2015 Conference call scheduled for 5:00 pm E.T. today with details below
PORTLAND, Ore., Nov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.